Neurotech International Ltd’s Post

The #FDA has approved marstacimab-hncq (Hympavzi; Pfizer) for routine prophylactic use or to reduce the frequency of bleeding episodes in adults and adolescents 12 years of age and older with #hemophilia A without factor VIII inhibitors, or with hemophilia B without factor IX inhibitors. This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen. https://ow.ly/kraz50TK4oy

Clotrimazole is an FDA approved drug and is widely used as an antifungal agent. An extensive body of research is available about its mechanism of action on various cell types but its mode of killing of Leishmania parasites is unknown. Leishmania causes Visceral Leishmaniasis which is a public health problem with limited treatment options. Its present chemotherapy is expensive, has adverse effects and is plagued with drug resistance issues. In this study we have explored the possibility of repurposing clotrimazole as an antileishmanial drug. We have assessed its efficacy on the parasites and attempted to understand its mode of action. Effect of clotrimazole was reduced by ergosterol supplementation. It leads to impaired parasite morphology. It alters plasma membrane permeability and disrupts plasma membrane potential. Mitochondrial function is compromised as is evident from increased ROS generation, depolarized mitochondrial membrane and decreased ATP levels. Cell cycle analysis of clotrimazole treated parasites shows arrest at sub-G0 phase suggesting apoptotic mode of cell death. A part of my PhD thesis is now published. Read here at: https://lnkd.in/ggcyM_Qx

New SGLT2 inhibitor meta-analysis on effect on HF- across diff populations  https://lnkd.in/e8b8KK7h

Advanced Cell Therapies Enhanced by Nanotein Technologies, Inc. and Akron Bio’s Partnership for cGMP Production of STEM-T Activator Nanotein Technologies, Inc. has partnered with Akron Bio to ensure the cGMP production of the NanoSpark™ STEM-T Soluble T Cell Activator for advanced cell therapies. This collaboration will provide high-quality, cGMP-compliant materials for clinical and commercial use, improving immune cell activation and supporting the development of T cell-based treatments. Akron Bio’s CEO, Chris Murphy, and Nanotein Technologies, Inc.’s CEO, Curtis Hodge, PhD, highlighted the importance of this partnership in advancing global cell therapies. Nanotein Technologies, Inc.'s future plans include cGMP production of their NK activation reagent, further contributing to the field of immunotherapy. For more details please click the link! https://lnkd.in/dfbV_bkp #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

Ziresovir, an experimental inhibitor of RSV infection, reduces the signs and symptoms of bronchiolitis in hospitalized infants and young children. Findings from a Phase 3 clinical trial show that this inhibitor, which targets the fusion viral protein, when administered twice daily for five days, causes significant clinical improvement and reduces viral load compared to placebo. The drug, developed by the Chinese company Shanghai Ark Biopharmaceuticals, did not reveal any safety concerns and demonstrated antiviral effects by day 3 of treatment. Notably, about 9% of patients treated with the fusion inhibitor acquired resistance mutations during the 5-day treatment, highlighting the need for combination therapy with multiple inhibitors to minimize the emergence of resistance. #RSV #children #infectiousdiseases #pediatric #health #globalhealth #publichealth #medicine #biotechnology #pharmaceuticals #WHO #CDC #China

Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis

Types of Antiretroviral Drugs Types of antiretroviral drugs. Patient education about antiretroviral therapy (ARVT). https://lnkd.in/dYg5ef4u

In new #raredisease work with Mike Lanthier, we constructed "family trees" of orphan drugs to answer the question: How (if at all) have orphan drugs expanded their labeled indications over time and what patient populations + diseases do these extensions include? We find that #orphandrugs are a heterogeneous group: the majority (52%) had only a single rare disease approval while 20% had approvals in both rare and common diseases. Additionally, we found there were 48 approvals that extended the labeled indication to include a #pediatric population of a rare disease. https://lnkd.in/dyqeqP64

Great article emphasizing the importance of incentives for #raredisease #drugdevelopment - including the Orphan Drug Act (#ODA) - to support #pediatric research (after all, more than half of all 7,000+ rare diseases impact children and many are fatal before adulthood), and the Inflation Reduction Act (#IRAs) potential stifling impact on future #raredisease research and the likelihood of follow-on indications in new therapeutic areas.

Meet Captain 3A4: The CYP3A4 Enzyme Powerhouse! 🌟 Last week on Thursday's edition of "Enzyme Avengers: The Catalysts of Change", we unveiled the mighty CYP superheroes who team up with our bodies to conquer medications. And now, get ready to cheer for one of the stars in our show: An ultimate guardian of your body's biochemistry: Captain 3A4!🦸♂️ Captain 3A4 is a master at breaking down a variety of drugs in your body. #learning To help you remember these drugs, we created a nifty mnemonic: "AC 4 A SHIP." It stands for: Analgesics Cardiovascular drugs Captain 3A4 is the enzyme Anticoagulants Statins HIV Drugs Immunosuppressants PDE5i Not every drug in these classes is majorly metabolized by CYP3A4, but a lot of them are. Understanding which drugs Captain 3A4 can handle is crucial. Why? #PatientSafety Because if a drug inhibits or induces Captain CYP3A4, it can affect how other medications that you take are broken down in your body, potentially leading to unwanted side effects or reduced effectiveness. This is where a PGx certified pharmacist can be your health ally! They can help with testing, prescribing, deprescribing, managing and preventing reactions related to drug metabolism, induction, or inhibition and so much more. 🧬💊 Stay tuned every Thursday for more #MedicineMagic insights as we follow the Epic Journey of our Enzyme Avengers: The Catalysts of Change and how they keep our bodies in balance! #healthcare #DNA2Dose #PGx